None listed
Conditions
Interventions
Intervention1: Drug code 141: To be administered in 6C, 12C, 30C and 200C potencies. 12 doses for each potency, Frequency- Four times a day, Route of administration- Oral
Control Intervention1: Place
Sponsors
Central Council for Research in Homoeopathy
Eligibility
Inclusion criteria
Inclusion criteria: 1.Healthy individuals with no apparent disease and normal routine laboratory parameters during screening 2.Healthy individuals identified as fit for proving by experts 3.Intelligent enough to record carefully the facts, subjective and objective symptoms generated by the IPS during proving. 4.Able to be informed of the nature of the study and willing to give written informed consent
Exclusion criteria
Exclusion criteria: 1.Any disease or condition which might compromise the hematopoietic, renal, endocrine, pulmonary, central nervous system, cardiovascular, immunological, dermatological, gastro-intestinal or any other body system 2.Persons with colour blindness. 3.Persons who have undergone surgery in last two months. 4.Planned medical / dental treatment during the proving period including herbal or dietary supplements, procedures, or medications that are likely to interfere with, or substantially alter, responsiveness to the proving substance. 5.Volunteers on regular medication (allopathic, ayurvedic, homoeopathic, naturopathic, unani, etc.) for any acute or chronic disease. 6.Participant must not be on any homoeopathic remedy in the preceding one month and have had no significant change in health status in last one month. 7.Emotionally disturbed, hysterical or anxious persons. 8.Persons having known history of allergies, food hypersensitivity, etc. 9.Women during pregnancy, puerperium and while breast-feeding and women who have undergone hysterectomy. 10.Smokers who smoke more than 10 cigarettes per day 11.Recent history of alcoholism / drug addictions or unlikely to refrain from excessive alcohol consumption / drug intake during the study period 12.Participation in another clinical or proving trial during the last 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathogenesis of drg code 141Timepoint: Approximately one year | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: Nil | — |
Countries
India
Contacts
Public ContactDr Pritha Mehra
Dr. D. P. Rastogi Central Research lnstitute of HomoeopathY
Outcome results
None listed